Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)
Sunday, April 7th – Thursday, April 11th
Registration starts at 4:00PM on Sunday
Beaver Run Resort
Meet us in Breckenridge April 7-11, as we attend this Keystone Symposia, organized by Christian Klein, Mark S. Cragg and Germaine Fuh. Learn about our immunogenicity screening tool that can predict antibody immunogenicity based on effector and regulatory T cell epitope content.
ABOUT THIS EVENT:
This Keystone Symposia conference aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential.
Over the last twenty years, recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds.
The conference will foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. It may also initiate collaborations on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For trainees and early career researchers, this conference provides an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field.
A unique component to this conference that distinguishes it from other more commercial meetings in the field, is that this conference will include presentation and discussion of novel/unpublished data.
For more information and/or to register, visit Keystone Symposia’s official event page.